Search Browse Earnings

Ayala Pharmaceuticals, Inc. — SlamSEC

Ayala Pharmaceuticals, Inc.

OTC:ADXS

Pharmaceutical Preparations·MONMOUTH JUNCTION, NJ

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$3.2M

+1180.6% YoY

FY 2022

Adj. EBITDA

-$37.3M

-1152.5% margin

FY 2023

Net Income

-$38.0M

-1173.2% margin

FY 2023

EPS (Diluted)

-$13.13

FY 2023

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$2.4M

FY 2023

Total Debt

$2.1M

FY 2013

Net Cash

$318,897

FY 2013

Enterprise Value

—

Debt / EBITDA

0.0x

FY 2022

EV / EBITDA

—

Employees

—